PLSE Starts Research Work on nPulse Technology to Treat Thyroid Tumor

Pulse Biosciences partners with MD Anderson to study its nPulse technology for treating benign and malignant thyroid tumors upon receiving FDA approval for a first-in-human trial.

Zacks Investment Research • Dec 10, 2025

Pulse Biosciences, Inc. Announces Initiation of Research Collaboration for the Treatment of Benign and Malignant Thyroid Tumors with nPulse™ Technology

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced a research collaboration with The University of Texas MD Anderson Cancer Center to examine the use of the Company's nPulse™ Vybrance™ Percutaneous Electrode System for treatment of thyroid cancers. The Investigational Device Exem.

Business Wire • Dec 9, 2025

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced that the Compensation Committee of its Board of Directors has granted equity awards to three new employees as equity inducement awards outside of the Company's 2017 Equity Incentive Plan, but under the terms of the 2017 Inducement Equity Incentive Plan. The equity awa.

Business Wire • Nov 21, 2025

Pulse Biosciences, Inc. Announces Participation in Upcoming Investor Conferences

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced plans to participate in two upcoming investor conferences. Stifel 2025 Healthcare Conference, in New York, New York. Management is scheduled to present on Thursday, November 13, 2025, at 2:40 pm ET. Piper Sandler 37th Annual Healthcare Conference, in New York, New Yor.

Business Wire • Nov 6, 2025

Pulse Biosciences, Inc. (PLSE) Q3 2025 Earnings Call Transcript

Pulse Biosciences, Inc. ( PLSE ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Paul LaViolette - President, CEO & Co-Chairman of the Board Jon Skinner - Chief Financial Officer Conference Call Participants Philip Taylor - Gilmartin Group LLC Suraj Kalia - Oppenheimer & Co. Inc., Research Division Presentation Operator Hello, and thank you for standing by. My name is Mark, and I will be your conference operator today.

Seeking Alpha • Nov 6, 2025

Pulse Biosciences Reports Business Updates and Third Quarter 2025 Financial Results

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced business updates and financial results for the third quarter ended September 30, 2025. Recent Business Highlights Soft Tissue Ablation Initiated a multi-center clinical study, PRECISE-BTN, for the treatment of benign thyroid nodules (BTN) with the nPulse Vybrance perc.

Business Wire • Nov 5, 2025

Pulse Biosciences, Inc (PLSE) Reports Q3 Loss, Lags Revenue Estimates

Pulse Biosciences, Inc (PLSE) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.16 per share a year ago.

Zacks Investment Research • Nov 6, 2025

Pulse Biosciences Announces First Enrollment in the NANOCLAMP AF Study

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced the enrollment of the first patient in its NANOCLAMP AF Study for the treatment of atrial fibrillation (AF). The successful first procedure was completed at St. Helena Hospital in St. Helena, California, with the nPulse™ Cardiac Surgical System following its recent FD.

Business Wire • Oct 24, 2025

Pulse Biosciences Schedules Third Quarter 2025 Business Updates and Financial Results Conference Call for November 5, 2025

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced it will report business updates and financial results for the third quarter 2025 after market close on Wednesday, November 5, 2025. Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET. Investors interested in listening to th.

Business Wire • Oct 22, 2025

Pulse Biosciences Unveils Promising First-in-Human Data for nPulse

PLSE unveils strong first-in-human data for its nPulse Cardiac Surgical System, showcasing safety, speed, and durable AF treatment potential.

Zacks Investment Research • Oct 13, 2025